Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines

Zosano Pharma (NASDAQ:ZSAN) has announced a publication has been released on its Phase 2/3 (ZOTRIP) study in Headache: The Journal of Head and Face Pain, titled “Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult to Treat Migraines.”

As quoted in the press release:

In this post-hoc analysis, researchers examined the efficacy of Qtrypta™ in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment.

Results from these post-hoc analyses using the same clinical endpoints of pain freedom and most bothersome symptom (MBS) at 2 hours from the ZOTRIP study demonstrated patients with these difficult-to-treat migraine characteristics had uniformly better headache responses compared to patients who received placebo.

“We are pleased with the results of this retrospective analysis, which demonstrate that Qtrypta may be an effective acute treatment for patients exhibiting migraine characteristics that historically have been difficult to treat,” said Dr. Stewart Tepper, M.D., Professor of Neurology at the Geisel School of Medicine at Dartmouth. “Qtrypta was found to have clinically and statistically significant impact on pain freedom and most bothersome symptom freedom across the entire patient population in the ZOTRIP study, and the results from these subset analyses support the potential for Qtrypta to provide patients with a novel acute treatment that provides rapid relief of pain in patients with these more refractory migraine subtypes.”

Click here to read the full press release.